# A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

> **NCT07365241** · PHASE3 · NOT_YET_RECRUITING · sponsor: **AbbVie** · enrollment: 531 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** ABBV-706
- **DRUG:** Topotecan
- **DRUG:** Topotecan
- **DRUG:** Lurbinectedin
- **DRUG:** Amrubicin

## Key facts

- **NCT ID:** NCT07365241
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-14
- **Primary completion:** 2030-09
- **Final completion:** 2030-09
- **Target enrollment:** 531 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07365241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07365241, "A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07365241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*